Titre:
  • Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Auteur:Dowsett, Mitch; Procter, Marion; McCaskill-Stevens, Worta; Azambuja, Evandro; Dafni, U; Rueschoff, J.; Jordan, B.; Dolci, Stella; Abramovitz, Mark; Stoss, Oliver; Viale, G; Gelber, R D; Piccart-Gebhart, Martine; Leyland-Jones, Brian
Informations sur la publication:Journal of clinical oncology, 27, 18, page (2962-2969)
Statut de publication:Publié, 2009-06
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Antibodies, Monoclonal -- therapeutic use
Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- genetics
Breast Neoplasms -- mortality
Disease-Free Survival
Female
Gene Amplification
Genes, erbB-2
Humans
Immunohistochemistry
Prognosis
Note générale:Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2008.19.7939
info:pii/JCO.2008.19.7939
info:pmid/19364966